<DOC>
	<DOCNO>NCT02207335</DOCNO>
	<brief_summary>Gemcitabine plus carboplatin recurrent metastatic breast cancer recommend scheme National Comprehensive Cancer Network ( NCCN ) guideline . gemcitabine combination capecitabine also effective Metastatic Breast Cancer ( MBC ) clinical study small sample .</brief_summary>
	<brief_title>Trial Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin Breast Cancer</brief_title>
	<detailed_description>A multicenter randomize phase â…¢ clinical trial gemcitabine combination capecitabine versus gemcitabine plus carboplatin first-line treatment triple-negative recurrent metastatic breast cancer.The primary endpoint study progression free survival ( PFS ) . The secondary endpoint overall response rate ( ORR ) , overall survival ( OS ) safety .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female 1870 year old ECOG 01 Expected lifetime 12 week Pregnancy Brain Metastasis , Severe Infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>